US Patent

US8155737 — Pharmacokinetics of iontophoretic sumatriptan administration

Method of Use · Assigned to NuPathe Inc · Expires 2027-04-12 · 1y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent describes improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan succinate.

USPTO Abstract

Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.

Drugs covered by this patent

sumatriptan-succinate (SUMATRIPTAN SUCCINATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1328`	—	sumatriptan-succinate

Patent Metadata

Patent number: US8155737
Jurisdiction: US
Classification: Method of Use
Expires: 2027-04-12
Drug substance claim: No
Drug product claim: No
Assignee: NuPathe Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.